Cooper (COO) Q3 2026 Earnings Call Transcript
Cooper Companies (COO) reported Q3 2026 revenue of $1.066B, up 1% organically, with non-GAAP EPS of $1.15, up 4% YoY. Free cash flow hit a record $273M. CooperVision revenue was flat, while CooperSurgical grew 3%. The company guided Q4 revenue to $1.057B-$1.080B and EPS to $1.05-$1.09. Management decided to retain CooperSurgical, citing better shareholder value than current transaction proposals. The company faces near-term revenue pressures from U.S. inventory reductions and macro headwinds in
How this was made
The 30-second read
Why it matters
Earnings beat and guidance raise expectations for continued cash generation, supporting the $3 bn share repurchase program.
Market read
First reporting of Q3 2026 results and FY guidance for a mid‑cap healthcare company; actionable for short‑term traders.
What to watch
Higher tax rate in FY2027 and FX headwinds could compress margins later in the year.
Background
Cooper Companies operates through CooperVision (contact lenses) and CooperSurgical (fertility and medical devices). The call covered Q3 results and FY2026‑2027 outlook.
Ticker impact
Q3 2026 earnings release with revenue, EPS, free cash flow numbers and FY guidance.
Potential short-term upside as investors price in stronger-than-expected earnings and higher guidance.
First disclosure of quarterly results and forward guidance; numbers exceed consensus and include record free cash flow, which typically drives buying pressure.
Market effects
Positive earnings may lift the broader eye‑care and medical device sector.
U.S. market may see modest gains; European markets less affected.
Limited to investors with exposure to Cooper Companies and related eye‑care stocks.
Counterpoint
Guidance is modest and inventory pressures remain; a pullback could occur if macro headwinds worsen.
Key entities
- ExecutiveAl White
President and CEO of Cooper Companies
- ExecutiveBrian Andrews
Chief Financial Officer of Cooper Companies
